期刊文献+

通过阻断花生四烯酸代谢途径抑制胰腺癌细胞增殖

Inhibition of arachidonic acid metabolism to decrease pancreatic cancer cell proliferation
下载PDF
导出
摘要 目的:探讨通过阻断花生四烯酸(arachidonic acid,AA)代谢途径抑制胰腺癌细胞增殖.方法:将胰腺癌细胞SW1990分为对照组,M K886干预组、塞莱昔布(C e l e c o x i b)干预组,MK886+Celecoxib干预组,用RT-PCR法检测细胞白三烯B4受体1(leukotriene B4receptor 1,BLT1)mRNA,血管内皮生长因子(vascular endothelial growth factor,VEGF)mRNA的表达量变化,用Western blot检测磷酸化-Erk(phosphorylated-extracellular regulated protein,p-Erk)表达量变化.结果:MK886作用下,BLT1 mRNA、VEGF mRNA等表达量均减少(P<0.01),p-Erk表达量明显减少(P<0.05),Celecoxib作用下,VEGF mRNA表达量明显减少(P<0.01),BLT1 mRNA表达与对照组无明显差异,p-Erk表达量与MK886组比较明显增加(P<0.01),MK886+80?mol/L Celecoxib作用下,BLT1 mRNA、VEGF mRNA表达量明显减少(P<0.01),p-Erk表达量与对照组无明显差异.结论:花生四烯酸的两条代谢途径均与胰腺癌的发生及增殖均有密切关系,而抑制5-脂氧合酶(5-lipoxygenase)途径较环氧化酶2(cyclooxygenase 2)途径相比,抑制肿瘤细胞增殖作用更强. AIM: To investigate the effect of inhibition of arachidonic acid metabolism on proliferation of pancreatic cancer cells. METHODS: Cultured pancreatic cancer SW1990 cells were treated with different concentrations of MK886, celecoxib, or MK886 + celecoxib. After treatment, the expression of leukotriene B4 receptor 1 (BLT1) and vascular endothelial growth factor (VEGF) mRNAs was detected by semi-quantitative RT-PCR and the expression of phosphorylated extracellular regulated protein (p-Erk) was measured by Western blot. RESULTS: Treatment with MK886 significantly decreased the expression of BLT1 and VEGF mRNAs (P 〈 0.01 for both) and p-Erk (P 〈 0.05).Treatment with celecoxib did not alter the expres- sion of BLT1 mRNA and decreased the expres- sion of VEGF mRNA compared with untreated cells (P 〈 0.01), but increased the expression of p-Erk compared with the MK886 group (P 〈 0.01). Treatment with MK886 and celecoxib significant- ly decreased the expression of BLT1 and VEGF mRNAs (P 〈 0.01 for both), but did not alter the expression of p-Erk. CONCLUSION: Both two pathways of ara- chidonic acid metabolism are associated with pancreatic cancer cell proliferation, with the pathway involving 5-1ipoxygenase being more important.
作者 朱陈 周国雄
出处 《世界华人消化杂志》 CAS 北大核心 2014年第8期1106-1111,共6页 World Chinese Journal of Digestology
关键词 胰腺癌细胞 花生四烯酸 MK886 CELECOXIB 5-脂氧合酶 环氧化酶-2 BLT1 血管内皮生长因子 磷酸化-Erk Pancreatic cancer cells Arachidonicacid MK886 Celecoxib 5-1ipoxygenase Cyclooxy-genase 2 LTB4 receptor 1 Vascular endothelialgrowth factor Phosphorylated extracellular regu-lated protein
  • 相关文献

参考文献16

  • 1Asuthkar S, Rao JS, Gondi CS. Drugs in preclinical and early-stage clinical development for pancreatic cancer. Expert Opin Investig Drugs 2012. 21:143-152 [PMID: 22217246 DOI: 10.1517/13543784.2012.651124].
  • 2Lionetto R, Pugliese V, Bruzzi P, Rosso R. No stan- dard treatment is available for advanced pancreatic cancer. Eur J Cancer 1995. 31A: 882-887 [PMID: 7646915 DOI: 10.1016/0959-8049(94)00445-5].
  • 3Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenoglio- Preiser CM, Abbruzzese JL, Blanke CD. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010. 28:3605-3610 [PMID: 20606093 DOI: 10.1200/ JCO.2009.25.7550].
  • 4Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey DJ, Choi W. Epithelial to mesenchymal transition contributes to drug re- sistance in pancreatic cancer. Cancer Res 2009. 69: 5820-5828 [PMID: 19584296 DOI: 10.1158/0008-5472.CAN-08-2819].
  • 5Qiu MT, Ding XX, Hu JW, Tian HY, Yin R, Xu L. Fixed-dose rate infusion and standard rate infu- sion of gemcitabine in patients with advanced non- small-cell lung cancer: a meta-analysis of six trials. Cancer Chemother Pharmaco12012. 70:861-873 [PMID: 23053260 DOI: 10.1007/s00280-012-1974-z].
  • 6Corrroy T, Desseigne F, Ychou M, Bouch O, Guim- baud R, Bcouarn Y, Adenis A, Raoul JL, Gourgou- Bourgade S, de la Fouchardire C, Bennouna J, Ba- chet JB, Khemissa-Akouz F, Pr-Verg D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Gril- lot C, Ducreux M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011. 364:1817-1825 [PMID: 21561347 DOI: 10.1056/NEJ- Moa1011923].
  • 7Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajesh- kumar NV, Maitra A, Hidalgo M. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011. 29:4548-4554 [PMID: 21969517 DOI: 10.1200/JCO.2011.36.5742].
  • 8Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol 2010. 66:1051-1057 [PMID: 20130876 DOI: 10.1007/ s00280-010-1257-5].
  • 9Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclo- oxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994. 107:1183-1188 [PMID: 7926468].
  • 10Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woemer BM, Koki AT, Fahey TJ. Cyclooxygenase-2 expres- sion is up-regulated in human pancreatic cancer. Cancer Res 1999. 59:987-990 [PMID: 10070951].

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部